GENOLUTION INC.
KKRX:2252201,620.00
KRW
0.00
(0.00%)
ISIN
KR7225220003
Return %
Stock
S&P 500
1Y
-27.52
13.14
3Y
-57.09
80.78
5Y
-76.71
67.74
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- Full Time Employees
- 76
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Seoul South Korea
- IPO Date
- Aug 3, 2015
- Website
- genolution.co.kr
- Similar Companies
- Business
- GENOLUTION INC. is a South Korea-based biotechnology company that specializes in the development, manufacturing, and commercialization of automated molecular diagnostics equipment, nucleic acid extraction solutions, and RNA interference (RNAi) technologies. Founded in 2006 and headquartered in Seoul, South Korea, the company operates primarily through two business segments: In-Vitro Diagnostics (IVD) and RNA Interference. Within its IVD division, Genolution provides automated magnetic bead-based nucleic acid extraction instruments under the Nextractor brand, including the Nextractor NX-Jr for compact laboratory operations, the Nextractor NX-48S and NX-48N for medium-to-high throughput specimen processing, and the Nextractor NX-Duo high-capacity extraction system; pre-filled viral, bacterial, genomic DNA, and total RNA extraction reagent cartridges and kits; automated extracellular vesicle and exosome isolation systems, including the Nx-Evo platform for oncology research and liquid biopsy applications; and associated molecular diagnostic consumables. Within its RNAi division, the company offers custom double-stranded RNA (dsRNA) and small interfering RNA (siRNA) synthesis services for gene function research; the proprietary AgroRNA platform for large-scale, high-yield dsRNA biomanufacturing; and eco-friendly agricultural biocontrol agents and veterinary gene therapies, including HoneyGuard-R for the treatment of Sacbrood virus infections in honeybees as well as dsRNA solutions targeting Varroa mites and crop pests. Genolution serves clinical diagnostic laboratories, medical centers, life science research institutes, agrigenomics enterprises, and biopharmaceutical developers across South Korea, Asia-Pacific, Europe, and the Americas. In recent operational developments, Genolution entered into a strategic collaboration with LGC Biosearch Technologies to integrate specialized nucleic acid purification chemistry into the Nextractor NX-Duo platform to accelerate penetration into global agrigenomics markets. Additionally, the company unveiled its Nx-Evo automated extracellular vesicle isolation platform to expand into clinical oncology diagnostics, obtained regulatory market authorization from South Korea's Animal and Plant Quarantine Agency for its HoneyGuard-R RNAi honeybee treatment, and advanced its production infrastructure across its Magok headquarters and Songdo research facilities.